IN2014DN07752A - - Google Patents
Info
- Publication number
- IN2014DN07752A IN2014DN07752A IN7752DEN2014A IN2014DN07752A IN 2014DN07752 A IN2014DN07752 A IN 2014DN07752A IN 7752DEN2014 A IN7752DEN2014 A IN 7752DEN2014A IN 2014DN07752 A IN2014DN07752 A IN 2014DN07752A
- Authority
- IN
- India
- Prior art keywords
- microbiota
- subject
- altering
- methods
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261604824P | 2012-02-29 | 2012-02-29 | |
PCT/US2013/028271 WO2013130773A2 (en) | 2012-02-29 | 2013-02-28 | Compositions of microbiota and methods related thereto |
US13/780,284 US9173910B2 (en) | 2012-02-29 | 2013-02-28 | Compositions of microbiota and methods related thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN07752A true IN2014DN07752A (zh) | 2015-05-15 |
Family
ID=49003107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN7752DEN2014 IN2014DN07752A (zh) | 2012-02-29 | 2013-02-28 |
Country Status (6)
Country | Link |
---|---|
US (11) | US9173910B2 (zh) |
EP (1) | EP2836224A4 (zh) |
CN (3) | CN110201003A (zh) |
BR (1) | BR112014021388A2 (zh) |
IN (1) | IN2014DN07752A (zh) |
WO (1) | WO2013130773A2 (zh) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3564357T (pt) | 2010-02-01 | 2022-06-14 | Rebiotix Inc | Bacterioterapia para colite por clostridium difficile |
EP2836224A4 (en) | 2012-02-29 | 2015-12-16 | Ethicon Endo Surgery Inc | COMPOSITIONS OF BIOZOOSE AND RELATED METHODS |
WO2014075745A1 (en) * | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
CN105378739B (zh) * | 2012-12-13 | 2019-09-27 | 麦太宝根有限公司 | 鉴定有发生2型糖尿病风险的人 |
GB2535034A (en) | 2013-07-21 | 2016-08-10 | Whole Biome Inc | Methods and systems for microbiome characterization, monitoring and treatment |
US9557331B2 (en) | 2013-08-23 | 2017-01-31 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9805171B2 (en) | 2013-08-23 | 2017-10-31 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US9526480B2 (en) | 2013-11-27 | 2016-12-27 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US9811641B2 (en) | 2013-08-23 | 2017-11-07 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US10152529B2 (en) | 2013-08-23 | 2018-12-11 | Elwha Llc | Systems and methods for generating a treatment map |
US20150057623A1 (en) * | 2013-08-23 | 2015-02-26 | Elwha Llc | Systems, Methods, and Devices for Delivering Treatment to a Skin Surface |
US9549703B2 (en) | 2013-11-27 | 2017-01-24 | Elwha Llc | Devices and methods for sampling and profiling microbiota of skin |
US10010704B2 (en) | 2013-08-23 | 2018-07-03 | Elwha Llc | Systems, methods, and devices for delivering treatment to a skin surface |
US9526450B2 (en) | 2013-11-27 | 2016-12-27 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US9610037B2 (en) | 2013-11-27 | 2017-04-04 | Elwha Llc | Systems and devices for profiling microbiota of skin |
US10206958B2 (en) | 2014-04-23 | 2019-02-19 | Cornell University | Modulation of fat storage in a subject by altering population levels of christensenellaceae in the GI tract |
EP3138031B1 (en) | 2014-04-28 | 2022-10-26 | Yeda Research and Development Co., Ltd. | Method and apparatus for predicting response to food |
WO2015178653A1 (ko) * | 2014-05-20 | 2015-11-26 | 이화여자대학교 산학협력단 | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 |
KR101740893B1 (ko) | 2014-05-20 | 2017-06-13 | 주식회사 엠디헬스케어 | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 |
WO2016033439A2 (en) * | 2014-08-28 | 2016-03-03 | Yale University | Compositions and methods for the treating an inflammatory disease or disorder |
US20170252399A1 (en) * | 2014-10-02 | 2017-09-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof |
CN108064132A (zh) | 2014-10-31 | 2018-05-22 | 霍勒拜欧姆公司 | 与病症的微生物治疗和诊断有关的方法和组合物 |
CA2974952C (en) * | 2015-01-26 | 2021-08-31 | International Dehydrated Foods, Inc. | Broth compositions and their use as prebiotics |
MX2017014111A (es) | 2015-05-06 | 2018-02-26 | Univ Wageningen | Uso de un polipéptido para efectuar la señalización inmune y/o afectar la función de barrera intestinal y/o modular el estado metabólico. |
ES2898930T3 (es) | 2015-06-01 | 2022-03-09 | Xeno Biosciences Inc | Composiciones para usar en la modulación de la microbiota intestinal y el manejo del peso |
EP3307906B1 (en) * | 2015-06-09 | 2020-10-14 | Regents of the University of Minnesota | Methods for detecting risk of having a bloodstream infection |
EP3943093A1 (en) * | 2015-09-10 | 2022-01-26 | Université catholique de Louvain | Use of pasteurized akkermansia for treating cancer |
WO2017100420A1 (en) * | 2015-12-08 | 2017-06-15 | Mayo Foundation For Medical Education And Research | Biomarkers for predicting clostridium difficile infection treatment outcome |
CN115887508A (zh) | 2016-03-04 | 2023-04-04 | 加利福尼亚大学董事会 | 微生物聚生体及其用途 |
TWI749004B (zh) * | 2016-04-15 | 2021-12-11 | 財團法人國家衛生研究院 | 抗肥胖微生物叢組合物及其製備方法與用途 |
EP3903766A1 (en) | 2016-04-19 | 2021-11-03 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Use of gram negative species to treat atopic dermatitis |
US10293005B2 (en) | 2016-04-19 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
US20180030403A1 (en) | 2016-07-28 | 2018-02-01 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
US10441612B2 (en) * | 2016-08-16 | 2019-10-15 | Taichung Veterans General Hospital | Intestinal microbe therapy, composition therefor and method for preparing the same |
US11311573B2 (en) | 2016-11-30 | 2022-04-26 | Xeno Biosciences Inc. | Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota |
CN107043714B (zh) * | 2016-12-13 | 2021-03-12 | 广州康泽医疗科技有限公司 | 一种益生菌及其制备方法 |
WO2018136884A1 (en) * | 2017-01-23 | 2018-07-26 | The Regents Of The University Of California | Compositions and methods for treating obesity and inducing weight loss |
JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス, インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
EP3695017A1 (en) * | 2017-10-13 | 2020-08-19 | Rebiotix, Inc. | Microbiome health index |
EP3723775A4 (en) | 2017-12-15 | 2022-04-13 | Solarea Bio, Inc. | MICROBIAL COMPOSITIONS AND METHODS OF TREATMENT OF TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME |
EP3735134A4 (en) * | 2018-01-04 | 2022-01-19 | White Dog Labs, Inc. | METHOD AND COMPOSITION FOR IMPROVING ANIMAL HEALTH COMPRISING ORGANIC CELLS CONSISTING OF STEM IN THE ORDER CLOSTRIDIALES |
EP3773645A4 (en) | 2018-04-10 | 2021-11-24 | Siolta Therapeutics, Inc. | MICROBIAL CONSORTIA |
US10973841B2 (en) | 2018-05-11 | 2021-04-13 | Forte Subsidiary, Inc. | Compositions for the treatment of skin conditions |
US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
EP3853605A4 (en) * | 2018-09-18 | 2022-07-06 | Mcpharma Biotech Inc. | DETECTION, TREATMENT AND MONITORING OF MICROBIOME-INDUCED METABOLIC DYSFUNCTION |
CN110964650B (zh) * | 2018-09-27 | 2022-10-11 | 上海上药信谊药厂有限公司 | 一种用于预防和治疗代谢疾病的菌株及其应用 |
ES2763874B2 (es) * | 2018-11-30 | 2020-10-13 | Consejo Superior Investigacion | Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades |
EP4010315A4 (en) * | 2019-08-09 | 2023-11-15 | The Regents of the University of California | COMPOSITIONS AND METHODS OF TREATING METABOLIC DISEASE |
US20240131081A1 (en) * | 2019-09-24 | 2024-04-25 | Healthbiome | Obligate anaerobic human intestinal microbe for cancer treatment, and use thereof |
EP4041264A1 (en) | 2019-10-07 | 2022-08-17 | Siolta Therapeutics, Inc. | Therapeutic pharmaceutical compositions |
DK180598B1 (da) * | 2020-02-21 | 2021-10-14 | Sander Wilbek Theis | Stivelsespropanoat anvendt som tilsætningsstof og/eller kosttilskud til mennesker til forebyggelse af overvægt og fedme |
CN111388488A (zh) * | 2020-04-10 | 2020-07-10 | 中国海洋大学 | 半乳寡糖及其衍生物在作为防治非酒精性脂肪肝药物中的应用 |
BR112023000719A2 (pt) * | 2020-07-17 | 2023-03-21 | Dsm Nutritional Products Llc | Composições de oligossacarídeo e métodos de uso |
BE1028339B1 (fr) | 2020-11-09 | 2021-12-21 | A Mansia Biotech | Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert |
WO2022155443A1 (en) * | 2021-01-15 | 2022-07-21 | Yale University | Compositions and methods for treating and preventing diseases or disorders using inter-species interactions |
WO2023002461A1 (en) | 2021-07-23 | 2023-01-26 | Universidade Católica Portuguesa - Ucp | Encapsulated bacterial, methods and uses thereof |
WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1423823A (fr) | 1964-11-20 | 1966-01-07 | Azote Office Nat Ind | Procédé de reformage catalytique et sous pression élevée des hydrocarbures pétroliers par la vapeur |
US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
CH671155A5 (zh) | 1986-08-18 | 1989-08-15 | Clinical Technologies Ass | |
US5143845A (en) | 1986-09-03 | 1992-09-01 | Toa Pharmaceutical Co., Ltd. | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
CA1333564C (en) | 1988-08-02 | 1994-12-20 | Thomas Julius Borody | Treatment of gastro-intestinal disorders |
JP2961182B2 (ja) | 1990-03-09 | 1999-10-12 | ミヤリサン株式会社 | クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物 |
JP2961184B2 (ja) | 1990-05-07 | 1999-10-12 | ミヤリサン株式会社 | クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物 |
CA2153391C (en) | 1993-01-11 | 2000-08-15 | Kenneth Rock | Inducing cytotoxic t lymphocyte responses |
GB9306473D0 (en) | 1993-03-29 | 1993-05-19 | Bioglan Lab Ltd | Pharmaceutically useful compounds |
US6241983B1 (en) | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
AU744156B2 (en) | 1996-10-28 | 2002-02-14 | General Mills Inc. | Embedding and encapsulation of controlled release particles |
JP2002525041A (ja) | 1998-09-17 | 2002-08-13 | ノース アメリカン ワクチン, インコーポレイテッド | 連鎖球菌性Cβタンパク質組成物 |
NZ512275A (en) | 1998-12-11 | 2003-11-28 | Urex Biotech Inc | Probiotic therapy delivered to women by oral administration of selected lactobascilli that have antagonistic properties against urogenital pathogens |
ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
US7056661B2 (en) | 1999-05-19 | 2006-06-06 | Cornell Research Foundation, Inc. | Method for sequencing nucleic acid molecules |
US6926891B1 (en) | 1999-08-05 | 2005-08-09 | Nestec S.A. | Treatment of diarrhea with strains of Bifidobacterium longum |
JP4580542B2 (ja) | 2000-05-17 | 2010-11-17 | 株式會社バイオニア | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 |
US20020013270A1 (en) | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
US20040062757A1 (en) | 2001-06-05 | 2004-04-01 | Finegold Sydney M. | Method of testing gastrointestinal diseases associated with species of genus clostridium |
FI110668B (fi) | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
EP1227152A1 (en) | 2001-01-30 | 2002-07-31 | Société des Produits Nestlé S.A. | Bacterial strain and genome of bifidobacterium |
BR0207019A (pt) | 2001-02-06 | 2004-02-25 | Nestle Sa | Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias |
WO2002085415A1 (en) | 2001-04-17 | 2002-10-31 | Biomatrix, Inc | Non-digestible sugar-coated products and process |
US7101565B2 (en) | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
DE60305159T2 (de) | 2002-02-21 | 2007-03-15 | Société des Produits Nestlé S.A. | Oral verabreichbare zusammensetzung zum schutz der haut vor licht |
ITBO20020564A1 (it) | 2002-09-06 | 2004-03-07 | Alfa Wassermann Spa | Bifidobatteri e preparazioni che li contengono. |
SE526711C2 (sv) | 2003-01-31 | 2005-10-25 | Probi Ab | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
WO2004101770A1 (en) | 2003-03-13 | 2004-11-25 | Universite De Moncton (Bureau De Soutien A L'innovation) | Antioxidant producing bacterium and uses thereof |
GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
EP1462116A1 (en) | 2003-03-29 | 2004-09-29 | Villitech SARL | Composition for treating the gastrointestinal tract |
US8192733B2 (en) | 2003-08-29 | 2012-06-05 | Cobb & Associates | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
US20050100559A1 (en) | 2003-11-07 | 2005-05-12 | The Procter & Gamble Company | Stabilized compositions comprising a probiotic |
EP1600060A1 (en) | 2004-05-25 | 2005-11-30 | Cognis IP Management GmbH | Oral and/or topical compositions comprising prebiotics and fatty acid |
KR20070070153A (ko) | 2004-06-23 | 2007-07-03 | 로레알 | 민감성 및/또는 건성 피부의 예방 및/또는 치료에 유용한방법 및 조성물 |
US7862808B2 (en) | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
ITMI20041550A1 (it) | 2004-07-29 | 2004-10-29 | Proge Farm Srl | Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide |
FR2874825B1 (fr) | 2004-09-08 | 2006-12-08 | Genibio Sarl | Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale |
US20060115485A1 (en) | 2004-10-29 | 2006-06-01 | Medimmune, Inc. | Methods of preventing and treating RSV infections and related conditions |
US20060115465A1 (en) | 2004-10-29 | 2006-06-01 | Macfarlane George | Treatment of gastrointestinal disorders |
BRPI0519426A2 (pt) | 2004-12-28 | 2009-01-20 | Meiji Seika Kaisha | linhagem conferindo propriedades antidoenÇa À composiÇço de cÉlula bacteriana e hospedeira |
TW200700074A (en) | 2005-03-04 | 2007-01-01 | Calpis Co Ltd | Inducer of t cell apoptosis |
US20070042953A1 (en) | 2005-08-16 | 2007-02-22 | Bazan Nicolas G | Antiepileptogenic complex of albumin with docosahexaenoate |
FR2889958A1 (fr) | 2005-08-25 | 2007-03-02 | Lyoct Sa Lab | Utilisation d'un symbiotique pour le traitement de la dermatite atopique |
EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
ITRM20060237A1 (it) | 2006-05-03 | 2007-11-04 | Anabasis S R L | Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche |
JP2009537547A (ja) * | 2006-05-18 | 2009-10-29 | バイオバランス エルエルシー | 生物学的治療組成物およびその使用 |
CN1850047A (zh) * | 2006-06-01 | 2006-10-25 | 济南帅华医药科技有限公司 | 一种含β-内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用 |
JP5019563B2 (ja) | 2006-06-16 | 2012-09-05 | 旭化成ケミカルズ株式会社 | 腸内細菌賦活剤 |
CN101095698B (zh) | 2006-06-26 | 2010-12-01 | 青岛东海药业有限公司 | 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途 |
US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
EP2102350A4 (en) | 2006-12-18 | 2012-08-08 | Univ St Louis | INTESTINAL MICROBIOMA AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESITY OR OBESITY-RELATED DISORDER |
US9644210B2 (en) | 2007-02-22 | 2017-05-09 | Jürgen Schrezenmeir | Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human |
KR20100016012A (ko) | 2007-03-28 | 2010-02-12 | 앨러멘터리 헬스 리미티드 | 프로바이오틱 비피도박테리움 스트레인 |
GB2460781B (en) | 2007-03-28 | 2012-01-25 | Alimentary Health Ltd | Probiotic bifidobacterium strains |
CA2684713C (en) | 2007-05-03 | 2019-02-19 | Tobias Olofsson | Lactobacillus or bifidobacterium isolated from honey or honey producing tracts of honey bees |
TW200904340A (en) | 2007-05-11 | 2009-02-01 | Mannatech Inc | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same |
DK1992351T3 (en) | 2007-05-18 | 2016-06-06 | Nestec Sa | Lactobacillus johnsonii for the prevention of post-surgical infection |
US20090010891A1 (en) | 2007-07-06 | 2009-01-08 | Toa Pharmaceutical Co., Ltd. | Sepsis Treatment Agent |
US20090010892A1 (en) | 2007-07-06 | 2009-01-08 | Toa Pharmaceutical Co., Ltd. | Hyperlipidemia Treatment Agent |
EP2184997A4 (en) | 2007-07-31 | 2010-11-03 | Univ New York | DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES |
EP2030623A1 (en) * | 2007-08-17 | 2009-03-04 | Nestec S.A. | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
US20100284979A1 (en) | 2007-10-01 | 2010-11-11 | University College Cork, National University Of Ireland, Cork | Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria |
US8478544B2 (en) | 2007-11-21 | 2013-07-02 | Cosmosid Inc. | Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods |
US20090143759A1 (en) | 2007-11-30 | 2009-06-04 | Jacques Van Dam | Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct |
EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
ES2343499B1 (es) | 2007-12-24 | 2011-06-10 | Consejo Superior De Investigaciones Cientificas | Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. |
EP2110028A1 (en) | 2008-04-15 | 2009-10-21 | Nestec S.A. | Bifidobacterium longum and hippocampal BDNF expression |
CN102089422B (zh) | 2008-07-11 | 2013-07-17 | 科.汉森有限公司 | 新的益生长双歧杆菌 |
US8569466B2 (en) | 2008-09-10 | 2013-10-29 | Nnochiri Ekwuribe | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers |
WO2010036876A2 (en) | 2008-09-25 | 2010-04-01 | New York University | Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota |
US20100087481A1 (en) * | 2008-10-03 | 2010-04-08 | Lee Kathleen M | Oral pharmaceutical formulations for antidiabetic compounds |
RU2570557C2 (ru) | 2008-11-11 | 2015-12-10 | Алиментари Хелс Лимитед | ПРОБИОТИЧЕСКАЯ БИФИДОБАКТЕРИЯ Bifidobacterium Longum |
JP6077303B2 (ja) | 2009-05-07 | 2017-02-08 | タト エ リル アングルディアント フランス ソシエテ パ アクシオンス シンプリフィエ | アルファ−(1,2)−分岐アルファ−(1,6)オリゴデキストランを含有する組成物及びアルファ−(1,2)−分岐アルファ−(1,6)オリゴデキストランの製造方法 |
MX336030B (es) | 2009-05-11 | 2016-01-07 | Nestec Sa | Lactobacillus johnsonii la1 mcc533 (cncm i-1225) y padecimientos inmunes. |
US20150320808A1 (en) | 2009-06-19 | 2015-11-12 | Dupont Nutrition Biosciences Aps | Bifidobacteria for treating cardiac conditions |
ES2729765T3 (es) | 2009-06-19 | 2019-11-06 | Dupont Nutrition Biosci Aps | Bifidobacterias para el tratamiento de la insuficiencia cardíaca congestiva |
US9848760B2 (en) | 2009-06-29 | 2017-12-26 | Gearbox, Llc | Devices for continual monitoring and introduction of gastrointestinal microbes |
CN102470152A (zh) | 2009-07-30 | 2012-05-23 | 丹尼斯科公司 | 用于治疗内毒素血症的乳酸菌和双歧杆菌 |
EP2289527B1 (en) | 2009-08-25 | 2018-02-21 | Nestec S.A. | Bifidobacterium longum and functional GI disorders |
CA2776420A1 (en) | 2009-10-05 | 2011-04-14 | Aak Patent B.V. | Methods for diagnosing irritable bowel syndrome |
US20110081320A1 (en) | 2009-10-06 | 2011-04-07 | Nubiome, Inc. | Treatment/Cure of Autoimmune Disease |
EP2498626B1 (en) | 2009-11-12 | 2015-06-17 | Nestec S.A. | Nutritional composition for promoting gut microbiota balance and health |
PL2513292T3 (pl) | 2009-12-16 | 2018-02-28 | Probiotical S.P.A. | Szczepy bakterii probiotycznych wytwarzające sprzężony kwas linolowy oraz ich zastosowanie do wytwarzania kompozycji farmaceutycznej |
US9504750B2 (en) | 2010-01-28 | 2016-11-29 | Advanced Bionutrition Corporation | Stabilizing composition for biological materials |
NL2004201C2 (en) | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
EP2556835B1 (en) | 2010-02-10 | 2015-08-05 | Japan Eco-Science Co. Ltd. | Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism |
IT1398553B1 (it) | 2010-03-08 | 2013-03-01 | Probiotical Spa | Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario. |
EP3202406A1 (en) | 2010-04-28 | 2017-08-09 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
FI20105478A0 (fi) | 2010-04-30 | 2010-04-30 | Valtion Teknillinen | Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi |
US8951512B2 (en) * | 2010-05-04 | 2015-02-10 | New York University | Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota |
WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性t細胞の増殖または集積を誘導する作用を有する組成物 |
EP2586448B1 (en) | 2010-06-28 | 2018-02-07 | Kabushiki Kaisha Yakult Honsha | Skin properties improving agent for oral administration |
EP2588070B8 (en) | 2010-06-30 | 2019-07-24 | Société des Produits Nestlé S.A. | USE OF CHICORIC ACID AND LACTIC BACTERIUM IN FOOD SUPPLEMENT FOR lightening and/or whitening skin tone |
WO2012024638A2 (en) | 2010-08-20 | 2012-02-23 | New York University | Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota |
WO2012033814A2 (en) | 2010-09-10 | 2012-03-15 | Viropharma Incorporated | Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use |
DK2944690T3 (en) | 2010-10-11 | 2018-04-03 | Jennewein Biotechnologie Gmbh | UNKNOWN FUCOSYL TRANSFERASES AND THEIR APPLICATIONS |
US20120165792A1 (en) | 2010-12-22 | 2012-06-28 | Ethicon Endo-Surgery, Inc. | Pill Catchers |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
WO2012118535A1 (en) | 2011-03-01 | 2012-09-07 | Quorum Innovations, Llc | Materials and methods for treating conditions associated with pathogenic biofilm |
ES2636439T3 (es) * | 2011-03-09 | 2017-10-05 | Regents Of The University Of Minnesota | Composiciones y métodos para el trasplante de microbiota de colon |
WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
ITMI20110793A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
CA2878005C (en) | 2011-08-17 | 2020-03-10 | Microbiome Therapeutics, Llc | Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodetes to microbiota of firmicutes phylum |
US9493737B2 (en) | 2011-08-18 | 2016-11-15 | Chr. Hansen A/S | Method for purifying bacterial cells |
RU2613322C2 (ru) | 2011-08-30 | 2017-03-15 | Академис Медис Сентрум | Способ профилактики и/или лечения инсулинорезистентности |
ES2662793T3 (es) | 2011-09-14 | 2018-04-09 | Nubiyota Llc | Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos |
US20130121968A1 (en) | 2011-10-03 | 2013-05-16 | Atossa Genetics, Inc. | Methods of combining metagenome and the metatranscriptome in multiplex profiles |
FI20116008A0 (fi) | 2011-10-12 | 2011-10-12 | Maeyrae Maekinen Annika | Viskeraalisen rasvan estäminen ja diagnostisointi |
US9649346B2 (en) | 2011-11-02 | 2017-05-16 | Bios Llc | Probiotic stick formulation for skin maintenance and methods of use |
JP6306507B2 (ja) | 2011-12-01 | 2018-04-18 | 国立大学法人 東京大学 | 制御性t細胞の増殖または集積を誘導するヒト由来細菌 |
SG11201402993XA (en) | 2011-12-07 | 2014-09-26 | Calpis Co Ltd | Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof |
EP2836224A4 (en) | 2012-02-29 | 2015-12-16 | Ethicon Endo Surgery Inc | COMPOSITIONS OF BIOZOOSE AND RELATED METHODS |
ES2436251B1 (es) | 2012-05-25 | 2014-10-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas. |
US20130344042A1 (en) | 2012-06-20 | 2013-12-26 | Gretchen Tanbonliong | Dietary management of celiac disease and food allergy |
WO2014011233A1 (en) | 2012-07-09 | 2014-01-16 | Trachtman Ira Milton | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
WO2014029758A1 (en) | 2012-08-20 | 2014-02-27 | Chr. Hansen A/S | Method for optimizing a process for freeze drying a bacteria-containing concentrate |
US20140079676A1 (en) | 2012-09-20 | 2014-03-20 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
WO2014070014A1 (en) | 2012-11-01 | 2014-05-08 | Rijksuniversiteit Groningen | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract |
WO2014075745A1 (en) | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
EP2919796B1 (en) | 2012-11-19 | 2021-04-28 | Université catholique de Louvain | Use of akkermansia for treating metabolic disorders |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
NZ709392A (en) | 2012-11-23 | 2016-10-28 | Seres Therapeutics Inc | Synergistic bacterial compositions and methods of production and use thereof |
KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
EP2951283A4 (en) | 2013-02-04 | 2017-01-25 | Seres Therapeutics, Inc. | Compositions and methods |
US20160040215A1 (en) | 2013-03-14 | 2016-02-11 | Seres Therapeutics, Inc. | Methods for Pathogen Detection and Enrichment from Materials and Compositions |
WO2014190251A1 (en) | 2013-05-24 | 2014-11-27 | Genomatica, Inc. | Microorganisms and methods for producing (3r)-hydroxybutyl (3r)-hydroxybutyrate |
CN105106245A (zh) | 2015-08-24 | 2015-12-02 | 上海交通大学医学院附属瑞金医院 | Akkermansia muciniphila BAA-835菌株的应用 |
CN105030841A (zh) * | 2015-08-24 | 2015-11-11 | 上海交通大学医学院附属瑞金医院 | Akkermansia muciniphila BAA-835菌株的应用 |
-
2013
- 2013-02-28 EP EP13754666.9A patent/EP2836224A4/en active Pending
- 2013-02-28 US US13/780,284 patent/US9173910B2/en active Active
- 2013-02-28 IN IN7752DEN2014 patent/IN2014DN07752A/en unknown
- 2013-02-28 WO PCT/US2013/028271 patent/WO2013130773A2/en active Application Filing
- 2013-02-28 BR BR112014021388A patent/BR112014021388A2/pt not_active Application Discontinuation
- 2013-02-28 CN CN201910088168.5A patent/CN110201003A/zh active Pending
- 2013-02-28 CN CN201810321009.0A patent/CN108771687A/zh active Pending
- 2013-02-28 CN CN201380022545.6A patent/CN104780932A/zh active Pending
-
2015
- 2015-09-23 US US14/862,663 patent/US10149867B2/en active Active
-
2017
- 2017-09-08 US US15/698,965 patent/US10149870B2/en active Active
-
2018
- 2018-10-12 US US16/159,021 patent/US20190046590A1/en active Pending
-
2019
- 2019-10-30 US US16/669,143 patent/US10729732B2/en active Active
- 2019-10-31 US US16/670,659 patent/US20200121733A1/en active Pending
- 2019-10-31 US US16/670,705 patent/US20200121736A1/en active Pending
- 2019-10-31 US US16/670,685 patent/US20200121734A1/en not_active Abandoned
- 2019-10-31 US US16/670,695 patent/US11590176B2/en active Active
-
2020
- 2020-03-26 US US16/830,881 patent/US20200237835A1/en active Pending
- 2020-03-26 US US16/830,801 patent/US20200246395A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200121732A1 (en) | 2020-04-23 |
US20200121733A1 (en) | 2020-04-23 |
US20190046590A1 (en) | 2019-02-14 |
US11590176B2 (en) | 2023-02-28 |
CN108771687A (zh) | 2018-11-09 |
US10149870B2 (en) | 2018-12-11 |
CN110201003A (zh) | 2019-09-06 |
US20200121736A1 (en) | 2020-04-23 |
WO2013130773A3 (en) | 2014-12-18 |
CN104780932A (zh) | 2015-07-15 |
WO2013130773A8 (en) | 2014-10-16 |
US10729732B2 (en) | 2020-08-04 |
EP2836224A4 (en) | 2015-12-16 |
US20200237835A1 (en) | 2020-07-30 |
BR112014021388A2 (pt) | 2017-07-18 |
WO2013130773A2 (en) | 2013-09-06 |
US20200121735A1 (en) | 2020-04-23 |
US20170368108A1 (en) | 2017-12-28 |
US20160113971A1 (en) | 2016-04-28 |
US20200121734A1 (en) | 2020-04-23 |
US10149867B2 (en) | 2018-12-11 |
US9173910B2 (en) | 2015-11-03 |
EP2836224A2 (en) | 2015-02-18 |
US20130224155A1 (en) | 2013-08-29 |
US20200246395A1 (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN07752A (zh) | ||
EP3904502A3 (en) | Compositions and methods | |
BR112015007985A2 (pt) | compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados | |
BR112014000380A2 (pt) | composição farmacêutica, métodos para tratamento e usos dos mesmos | |
EA031157B9 (ru) | Вводимая перорально кортикостероидная композиция | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
WO2014062720A3 (en) | Methods of treating cancer | |
MX2021000715A (es) | Composiciones y metodos para tratar trastornos metabolicos. | |
BR112015000150A2 (pt) | composições farmacêuticas dissuasoras de abuso de liberação controlada | |
MX2013003282A (es) | Materiales y metodos para mejorar la funcion gastrointestinal. | |
BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
MX340822B (es) | Formulaciones para suministro oral de adsorbentes en el intestino. | |
MX2013003034A (es) | Lactamas piperidinilo-substituidas como moduladores de gpr119. | |
IN2015DN03219A (zh) | ||
BR112015000136A2 (pt) | fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento | |
MX2014013499A (es) | Moduladores alostericos de receptor alfa 7 nicotinico de acetilcolina, sus derivados y usos de los mismos. | |
MX340985B (es) | Compuestos de n-heteroarilo. | |
BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
WO2014030049A3 (en) | Compositions comprising a single variable domain and camostat mesylate (cm) | |
WO2014194226A3 (en) | Methods of treatment and compositions with xanthine oxidase inhibitors | |
PH12016501059A1 (en) | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation | |
MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
CL2017000884A1 (es) | Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica | |
BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce |